Lonsurf trifluridine/tipiracil regulatory update

Japan's Ministry of Health, Labor and Welfare (MHLW) approved Lonsurf trifluridine/tipiracil from Taiho to treat unresectable advanced or recurrent colorectal cancer refractory to standard therapies. Taiho said it plans to launch Lonsurf once Japan's National Health Insurance determines a price, which is expected in late May. The company said approval was based on primarily on data from a double-blind, placebo-controlled, Japanese Phase II trial of Lonsurf. Taiho is conducting the international Phase III RECOURSE trial of the product in patients with metastatic colorectal cancer refractory to standard chemotherapies. ...